MLM Biologics wins defense award to develop device for infection prevention in battlefield wounds

MLM Biologics, a Gainesville-based medical device innovator specializing in collagen-based wound healing solutions, has secured approximately $1.5 million in funding from the U.S. Army Medical Research and Development Command (USAMRDC). The non-dilutive award—channeled through the Department of Defense’s Military Prototype Advancement Initiative—aims to accelerate the development of a novel infection-preventing medical device for use in battlefield trauma scenarios.

The device under development is designed specifically for “complex, traumatic, penetrating injuries in a far-forward, austere environment,” according to public documents detailing the award. This marks a significant step forward for military-focused medtech, combining innovation in tissue engineering with targeted applications in combat care.

What specific need is MLM Biologics addressing with this new battlefield wound treatment device?

In military trauma medicine, wound infection remains a leading cause of complications, particularly in frontline environments where access to surgical intervention and sterilization is limited. MLM Biologics aims to tackle this issue by building a medical device that combines its proprietary collagen stabilization technology with known anti-inflammatory and antimicrobial components.

This combination is expected to result in a dual-action material that not only promotes faster tissue regeneration but also prevents the microbial colonization of wounds. The U.S. Army’s funding reflects a broader shift toward preemptive wound care—particularly solutions that are lightweight, shelf-stable, and easy to deploy in field operations.

How does MLM Biologics’ collagen technology contribute to wound healing and infection control?

MLM Biologics has previously gained attention for its bio-ConneKt® Wound Matrix, a U.S. Food and Drug Administration (FDA)-cleared product that uses proprietary collagen processing techniques to promote wound closure. Unlike traditional wound care products that rely solely on maintaining moisture or controlling exudate, the bio-ConneKt platform focuses on biological activity—encouraging cell migration, vascularization, and organized tissue growth.

This foundational technology forms the basis for the new military-focused device, which will add embedded bioactive agents that further reduce infection risk. According to company executives, the project aligns closely with the biotech firm’s longstanding vision of not merely managing wounds, but facilitating full, functional closure.

What is the military and civilian significance of this infection-preventing wound device?

Chandra Nataraj, Chief Executive Officer of MLM Biologics, emphasized the dual-use potential of the product. Speaking after the award announcement, Nataraj stated that the company’s focus has always been on wound closure rather than just wound management. He added that this new device could deliver meaningful benefits to America’s service members operating in hostile environments and eventually serve broader populations dealing with infection-prone injuries.

“The potential health benefits are huge,” he remarked, alluding to the device’s possible impact across trauma, surgical, and emergency wound care in both military and civilian settings.

How does this grant fit into the broader military medtech R&D ecosystem?

The funding was awarded through the Military Prototype Advancement Initiative (MPAI), an initiative under the Department of Defense that is executed in collaboration with the Medical Technology Enterprise Consortium (MTEC). MTEC is a public-private partnership that streamlines research cooperation between private industry, academia, and military research arms such as USAMRDC.

By working with MTEC, MLM Biologics gains access not only to funding but also to a broader collaborative ecosystem that accelerates defense-grade healthcare innovations. This approach has become an increasingly popular method for rapidly bringing prototypes to clinical use under Department of Defense priorities.

What role does the University of Florida’s UF Innovate program play in this partnership?

MLM Biologics conducts its research and development activities from its laboratory at the UF Innovate | Accelerate @ Sid Martin Biotech incubator in Alachua, Florida. Operated by the University of Florida, the accelerator provides infrastructure and mentoring support to emerging life sciences companies aiming to commercialize novel technologies.

Karl R. LaPan, director of UF Innovate | Accelerate, described MLM Biologics’ latest project as a textbook example of how public-private partnerships can turn university-adjacent research into high-impact, life-saving products. “This is exactly the kind of innovation ecosystem we’re trying to foster,” LaPan said, highlighting the translation of early-stage science into real-world defense and healthcare applications.

What products and expertise does MLM Biologics already have in the wound care market?

MLM Biologics is already known for its FDA-cleared bio-ConneKt® Wound Matrix, a biologically active matrix indicated for a wide variety of acute and chronic wounds including diabetic ulcers, pressure ulcers, and surgical wounds. Distributed out of the firm’s Gainesville headquarters, the product has seen adoption among clinicians seeking enhanced healing outcomes beyond standard dressings.

The biotech firm’s expertise centers on the use of preserved, stabilized collagen scaffolds that mimic the natural extracellular matrix. This strategy has proven effective in stimulating dermal regeneration and minimizing scarring. The new military-focused device will extend this core platform with added infection control capabilities tailored to field use.

What does this development signal for future biotech collaborations with U.S. defense agencies?

The award reaffirms the U.S. Department of Defense’s growing interest in tapping into civilian biotech innovation to meet military readiness and health needs. By selecting smaller, nimble medtech companies such as MLM Biologics, defense agencies are increasingly leveraging niche technological capabilities that may not yet be commercial blockbusters but offer high strategic value.

This model has allowed the U.S. Army to move faster in prototyping novel tools that are highly specialized for battlefield conditions—whether it involves wound care, regenerative medicine, or combat casualty treatment protocols. For firms like MLM Biologics, such contracts provide not only capital but also validation, visibility, and future potential in the government contracting landscape.

How might this innovation reshape wound care beyond the battlefield?

While the primary purpose of this new device is to serve military needs in extreme environments, the long-term commercial implications are broader. If successful, the collagen-based, infection-preventing matrix could be adapted for civilian trauma centers, rural hospitals, disaster response units, and global health NGOs operating in resource-limited settings.

MLM Biologics’ work on this project showcases how defense investments can spill over into healthcare innovation more broadly, setting the stage for crossover products that improve outcomes far beyond the battlefield.

As U.S. defense agencies continue to invest in medical readiness through targeted R&D awards, this Gainesville-based firm is positioned at the intersection of tactical necessity and medical advancement.